SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Walsh D) ;hsvcat:3"

Sökning: WFRF:(Walsh D) > Medicin och hälsovetenskap

  • Resultat 1-10 av 92
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
6.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
7.
  •  
8.
  • Weiner, D. J., et al. (författare)
  • Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders
  • 2017
  • Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 49:7
  • Tidskriftsartikel (refereegranskat)abstract
    • Autism spectrum disorder (ASD) risk is influenced by common polygenic and de novo variation. We aimed to clarify the influence of polygenic risk for ASD and to identify subgroups of ASD cases, including those with strongly acting de novo variants, in which polygenic risk is relevant. Using a novel approach called the polygenic transmission disequilibrium test and data from 6,454 families with a child with ASD, we show that polygenic risk for ASD, schizophrenia, and greater educational attainment is over-transmitted to children with ASD. These findings hold independent of proband IQ. We find that polygenic variation contributes additively to risk in ASD cases who carry a strongly acting de novo variant. Lastly, we show that elements of polygenic risk are independent and differ in their relationship with phenotype. These results confirm that the genetic influences on ASD are additive and suggest that they create risk through at least partially distinct etiologic pathways.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 92
Typ av publikation
tidskriftsartikel (89)
forskningsöversikt (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (88)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
Walsh, D (10)
Walsh, C (10)
Werge, T (9)
Mattheisen, M (9)
Meier, S (9)
Ripke, S (9)
visa fler...
Palotie, A (9)
Gill, M. (9)
Andreassen, OA (8)
Lubinski, J (8)
Stefansson, K (8)
Daly, MJ (8)
Williams, S. (7)
Alexander, M. (7)
Agartz, I (7)
Melle, I (7)
Pato, CN (7)
Pato, MT (7)
Craddock, N (7)
Rujescu, D (7)
Hultman, CM (7)
Magnusson, PKE (7)
Morris, DW (7)
Muller-Myhsok, B (7)
Smoller, JW (7)
Levinson, DF (7)
Wray, NR (7)
Degenhardt, F (7)
Schulze, TG (7)
Shi, JX (7)
Neale, BM (7)
Cloninger, CR (7)
Herms, S. (7)
Bergen, SE (7)
Strohmaier, J (7)
Frank, J (7)
Witt, SH (7)
Kendler, KS (7)
O'Donovan, MC (7)
Reichenberg, A. (7)
Engel, C. (7)
Neuhausen, SL (7)
Blackwood, DHR (7)
Owen, MJ (7)
Posthuma, D (7)
Buxbaum, JD (7)
Dudbridge, F (7)
Holmans, PA (7)
Giegling, I (7)
Hartmann, AM (7)
visa färre...
Lärosäte
Karolinska Institutet (50)
Lunds universitet (33)
Göteborgs universitet (32)
Umeå universitet (15)
Uppsala universitet (13)
Linköpings universitet (9)
visa fler...
Örebro universitet (6)
Stockholms universitet (2)
Mittuniversitetet (2)
Sveriges Lantbruksuniversitet (2)
Högskolan i Halmstad (1)
Mälardalens universitet (1)
Jönköping University (1)
Chalmers tekniska högskola (1)
Gymnastik- och idrottshögskolan (1)
visa färre...
Språk
Engelska (92)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (91)Ta bort avgränsningen
Naturvetenskap (7)
Samhällsvetenskap (2)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy